Status:
ACTIVE_NOT_RECRUITING
Comparison of Recurrence Rate of Keloid After Excision Between Intra-operative Steroid Injection and Steroid With Platelet-rich Plasma Injection Combination Therapy
Lead Sponsor:
Ramathibodi Hospital
Conditions:
Patients With Keloid Scar
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Keloid scars are benign skin lesions characterized by excessive collagen deposition, and their treatment remains challenging due to a high recurrence rate even after surgical excision. Combination the...
Eligibility Criteria
Inclusion
- Aged 18 years or older
- Having keloid scars less than 10 centimeters in length
- Undergoing complete keloid excision (extralesional excision)
- Undergoing surgery under local anesthesia
Exclusion
- Patients currently receiving immunosuppressive drugs or systemic steroids
- Patients with chronic diseases under active treatment, such as tuberculosis
- Pregnant or breastfeeding women
- Patients likely to have poor treatment adherence, such as those with cancer, epilepsy, or psychiatric disorders
- Patients with vascular diseases or hematologic/coagulation abnormalities
Key Trial Info
Start Date :
April 28 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2026
Estimated Enrollment :
212 Patients enrolled
Trial Details
Trial ID
NCT06965088
Start Date
April 28 2025
End Date
September 30 2026
Last Update
May 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Surgery, Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Bangkok, Bangkok, Thailand, 10140